EPISODE · Dec 10, 2024 · 5 MIN
Day 3 Highlights from ASH 2024: Lymphoma Breakthroughs and Myeloma Insights
from Curie: Healthcare in Focus
Day 3 of ASH 2024 revealed groundbreaking findings: a 97% complete response rate for zilovertamab vedotin in diffuse large B-cell lymphoma, new insights into zanubrutinib’s efficacy in chronic lymphocytic leukemia, and promising survival data for belantamab mafodotin in multiple myeloma. Like what you hear? Download Curie from the App Store for more personalized healthcare content.
Embed this episode
NOW PLAYING
Day 3 Highlights from ASH 2024: Lymphoma Breakthroughs and Myeloma Insights
0:00
5:34
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Curie: Healthcare in Focus?
This episode is 5 minutes long.
When was this Curie: Healthcare in Focus episode published?
This episode was published on December 10, 2024.
Can I download this Curie: Healthcare in Focus episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!